NCT02815137Completed
Detection and Prognostic Value of Recurrent XPO1 Mutations of Patients With Classical Hodgkin Lymphoma
Prevalence, Kinetic and Prognostic Value of XPO1 E571K Mutation Detection in Plasma Cell-free DNA From Patients Xith Classical Hodgkin Lymphoma
Source: ClinicalTrials.gov · Last updated 2 Jan 2026
Brief summary (registry, in English)
The purpose of this study is to determine if the XPO1 E571K mutation could be used as molecular residual disease biomarker in classical Hodgkin's lymphoma. To determine the interest of the mutation assessment by digital Polymerase Chain Reaction, sensitivity and specificity after 2 courses of chemotherapy (C2) will be compared with the deltaSUVmax determined by Positron Emission Tomography after C2 and at end of treatment.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 137 (actual)
- First submitted
- 13 Jun 2016
- Start date
- 1 Jun 2016
- Primary completion date
- 7 Dec 2021
- Lead sponsor
- Centre Henri Becquerel
- Diseases
- Hodgkin lymphoma
- NCT number
- NCT02815137
What you commit to
- Study type: Interventional
- Participants enrolled: 137
- From 1 Jun 2016 to the primary completion date, 7 Dec 2021
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previously treated Hodgkin lymphoma (including corticosteroids)
Other illness
- Active Hepatitis B or Hepatitis C infection
- Known human immunodeficiency virus (HIV) infection - Patient with no social protection
Other
- No informed consent
- Treatment by ABVD or BEACOPP not indicated
- Patients who are pregnant or lactating
- Patient under tutorship or curatorship
- Patient not affiliated of beneficiary of a benefit system
- Medical contraindication to PET/CT
Who the study is looking for
- Age ≥18 years
- Pathologically confirmed, recent diagnosis of classical Hodgkin Lymphoma
- treatment planned with Adriamycin Bleamycin Vinblastine Dacarbazine (ABVD) or Bleomycin Etoposide Adriamycin Cyclophosphamide Vincristine Procarbazine Prednisone (BEACOPP) regimen (and radiotherapy if applicable)
- all stages (Ann Arbor I - IV)
- Written informed consent
- Patient affiliated or beneficiary of a benefit system
- untreated patient (no corticosteroids or chemotherapy)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre Henri Becquerel Coordinator of this site? Confirm its status | Rouen | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.